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Multidisciplinary management is the standard of care for
common cancer subtypes, and it is particularly important
for rare cancers such as penile cancer. Often clinical expertise
may have to be concentrated into defined regional or supra-
regional cancer centres; thus patients may have to be treated
at centres distant from their home town. For comprehensive
management of the needs of penile patients, close communi-
cation is needed between the specialist cancer teams and lo-
cal medical services, including community support services,
particularly in the aftercare of surgery, for follow-up and in
the palliative management of end-stage disease.2. Background (epidemiology, incidence, path
and biology)
Penile cancer is relatively rare, representing about 0.5% of
male cancers. It has an incidence in Western societies esti-
mated at 1:100,000 [1]; a higher incidence is reported in
non-Western societies such as South America, Africa (partic-
ularly Uganda) and Asia. Whilst it is more prevalent in older
men, about 25% of cases are found in men younger than
40 years of age and about 10% in men under 30 years of age
[2].
Predisposing factors include both cultural and religious
practices as well as social and hygienic habits [3]. Of these,
circumcision in newborns and before puberty, together with
good hygiene, is associated with a reduced risk (by 3–4-fold)
of penile cancer. Other risk factors include smoking [4], phi-
mosis, inflammatory conditions such as lichen sclerosus or
balanoposthitis, ultraviolet radiation [5] and the presence of
human papilloma virus (HPV) that is related to sexual
promiscuity. However, there is no clear evidence yet that the
presence of HPV in penile cancer confers a worse prognosis
[6], but rather that it may predict a favourable outcome [7].The major histopathological subtype is squamous-cell car-
cinoma (SCC), and this entity represents 95% of penile can-
cers. Other subtypes include melanoma and basal-cell
carcinoma. Herein we will concentrate on malignant SCC of
the penis. It has been reported that penile SCC may demon-
strate four different patterns of growth [8] differing in natural
history and prognosis [9]: superficial spreading, vertical
growth, verrucous growth and multicentric growth. This will
be relevant to surgical management to ensure that any surgi-
cal resection adequately encompasses the potential patterns
of spread.3. TNM (primary tumour, regional nodes and
metastasis) classification
The 2009 TNM classification listed in Table 1 has provided an
update for the T1 category but still suffers from limitations
in the T2 category, where corpus spongiosum involvement
has been reported to be associated with a better prognosis
than corpora cavernosa involvement [10]. Another limitation
of the current TNM system is the lack of differentiation be-
tween T2 and T3 disease. One improvement is that the iden-
tification of retroperitoneal nodal disease is now accurately
regarded as extra-regional disease or distant metastasis
(M1).4. Prognostic factors
Early diagnosis and adequate staging is crucial to ensure that
management is organised appropriately. Full examination of
thepenisandparticularlyof thesurroundingnodaldrainagere-
gions is needed, as the primary drainage of thepenis is into the
inguinalnodes.Intheclinicallynegativeinguinaltheuseofultra-
sound may identify suspicious nodes suitable for fine-needle
aspiration (FNA). Recent advances and improved techniques44 20 7811
Table 1 – TNM classification of penile cancer.
T Primary tumour
T0 No evidence of primary tumour
Tis Carcinoma in situ
Ta Non-invasive verrucous carcinoma, not associated with destructive invasion
T1 Tumour invades subepithelial connective tissue
T1a Tumour invades subepithelial connective tissue without lymphovascular invasion and is not poorly
differentiated or undifferentiated (T1G1-2)
T1b Tumour invades subepithelial connective tissue without with lymphovascular invasion or is poorly
differentiated or undifferentiated (T1G3-4)
T2* Tumour invades corpus spongiosum/corpora cavernosa
T3 Tumour invades urethra
T4 Tumour invades other adjacent structures
N Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No palpable or visibly enlarged inguinal lymph node
N1 Palpable mobile unilateral inguinal lymph node
N2 Palpable mobile multiple or bilateral inguinal lymph nodes
N3 Fixed inguinal nodal mass or pelvic lymphadenopathy, unilateral or bilateral
M Distant metastases
M0 No distant metastasis
M1 Distant metastasis
pN Regional lymph nodes
pNX Regional lymph nodes cannot be assessed
pN0 No regional lymph node
pN1 Intranodal metastasis in a single inguinal lymph node
pN2 Metastasis in multiple or bilateral inguinal lymph nodes
pN3 Metastasis in pelvic lymph node(s), unilateral or bilateral or extranodal extension of regional lymph node metastasis
G Histopathological grading
GX Grade of differentiation cannot be assessed
G1 Well-differentiated
G2 Moderately differentiated
G3–4 Poorly differentiated/undifferentiated
* Ref. [20]
304 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 3 0 3 –3 0 6for sentinel-node biopsy have provided better identification of
the relevant inguinal node(s) and have permitted extraction of
the node for full histological evaluation compared with the
limitationsofusingFNA.
5. Clinical presentation and diagnosis
It is important to make a detailed examination of the penis
with attention to the dimensions and location of the lesion
and its relationship to the musculature of the penis. A deep
biopsy is needed in equivocal cases, with dorsal slitting if
there is a tight phimosis. Full assessment of the regional
drainage regions, i.e., inguinal, is mandatory. If there are pal-
pable nodes, then an FNA with or without ultrasound guid-
ance should be undertaken. Further staging of the pelvis
and abdomen will be needed using a computed tomography
(CT) scan of the thorax, abdomen and pelvis. The role of mag-
netic resonance imaging (MRI) and positron emission tomog-
raphy (PET) staging has not been fully established and
remains under investigation. In clinical cases of negative
inguinal nodes, where there is moderate to high risk of nodal
involvement (PT1 G2), then dynamic sentinel node examina-
tion should be undertaken. The management schema de-
scribed herein provides the policy guidelines followed
within our supra-regional centre, one of the largest services
within the United Kingdom.6. Management of primary disease
Ta lesions are treated conservatively, usually with circumci-
sion for lesions located over the prepuce, whilst lesions on
the glans can be treated using a wide local excision for smal-
ler lesions, or for larger lesions a total glans resurfacing or
glansectomy.
T1 lesions of the prepuce are treated with circumcision,
while lesions on the glans can be managed by either penis-
preserving surgery or radiotherapy. Penis-preserving surgery
may utilise a wide local excision that may include skin graft-
ing or glansectomy and skin grafting. Radiotherapy may be
delivered using external-beam irradiation or brachytherapy
which is the implantation of radioactive wires within the
vicinity of the extent of the lesion.
T2/T3 lesions of the penis can also be treated conserva-
tively with surgery if there is only distal involvement of the
glans and/or corporal heads, but frozen sections of the resec-
tion margins are needed to ensure adequacy of surgical clear-
ance. The penis-preserving surgical methods include
glansectomy and skin-graft reconstruction, or glansectomy
and distal corporectomy and reconstruction. If clinically
appropriate, penis preservation may also be considered for
proximal lesions. In these cases, delayed reconstruction with
a penile lengthening procedure may be considered. If penis
preservation surgery is not possible, then another alternative
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tomy with perineal urethrostomy.
T4 lesions of the penis often require multimodal therapy
for adequate local control. Down-staging with neo-adjuvant
chemotherapy should be considered. The standard chemo-
therapy is usually a platinum-based regimen, often in combi-
nation 5-fluoro-uracil (5-FU) or capecitabine. The surgery is
a penectomy with perineal urethrostomy. Alternatively,
radiotherapy can be considered for local control in selected
cases.
7. Management of the regional nodes
7.1. Clinically node negative at presentation
G1 Ta to T1 disease: in these cases, those patients with a neg-
ative ultrasound and FNA are at very low risk of nodal disease
and they can safely be observed.
G2 T1 lesions and above or T2 lesions G1-3: those patients
with both a negative ultrasound FNA and dynamic sentinel
node study are managed with surveillance. The surveillance
programme involves clinical 2-monthly follow-up for the first
year, 3-monthly follow-up for the second year and 4-monthly
follow-up for the third year. During each follow-up visit, a full
physical examination of the region is conducted, with ultra-
sound examination of the inguinal regions. A CT scan is
undertaken only where there are specific clinical indications.
For patients in whom the ultrasound FNA or dynamic sentinel
node study is possible, then a modified radical inguinal node
dissection will be performed on the ipsilateral side, with
observation of the contralateral inguinal region. In these
cases, all patients should have a staging CT scan of the tho-
rax, abdomen and pelvis as a baseline, and this should be re-
peated every 6 months for 3 years.
7.2. Clinically node positive at presentation
Those patients with clinically positive nodal disease should
receive a modified radical inguinal-node dissection on the
ipsilateral side and a dynamic sentinel-node study on the
contralateral side. Baseline CT staging is also needed, with
any other imaging based on clinical indications.
Those patients who have been found to have extracapsular
disease involvement should be offered postoperative radio-
therapy to the ipsilateral region. For patients with multiple
or bilateral superficial nodes, then bilateral inguinal-node dis-
section should be performed with consideration of pelvic no-
dal dissection. Postoperative radiotherapy should be offered
in the presence of extracapsular disease involvement of the
inguinal or pelvic nodal regions. Alternatively, if pelvic-node
dissection cannot be undertaken, then external-beam radio-
therapy can be used to cover the regions of risk together with
the inguinal regions of extracapsular disease involvement. If
there is large-volume pelvic disease then consideration
should be directed towards combination therapy using che-
mo-radiation to the pelvis followed by consolidation chemo-
therapy or initial chemotherapy followed by chemo-
radiation to the pelvis. There are currently no evidence-based
data on the most suitable management course or sequence of
therapies in these cases.Chemotherapy for node-positive or high-risk disease is not
given routinely. Where possible, recruitment into clinical tri-
als of adjuvant therapy is strongly encouraged.
7.3. Fixed or fungating inguinal nodes
In this situation, palliative inguinal-node dissection with
appropriate covering flaps undertaken by a supporting plastic
surgery team should be considered. External-beam radiother-
apy may also be used postoperatively if there is extensive
residual disease or as monotherapy for symptomatic pallia-
tive intent.7.4. Metastatic disease
The common sites of metastatic penile cancer disease are in
the lungs, liver or nodal regions outside of the pelvis. The
aim of palliative chemotherapy is to limit disease progression
and to improve symptomswith the aim of maintaining a good
quality of life for a good duration. Chemotherapy regimens
are usually platinum-based (cisplatin or carboplatin, depend-
ing on renal clearance) in combination with either capecita-
bine or 5-fluorouracil. Other regimens include the
combinations of carboplatin, methotrexate and bleomycin if
fluoropyrimidines are contraindicated for cardiovascular dis-
ease. Alternatively taxane-containing regimens have been
used. For localised metastatic lesions, palliative radiotherapy
is effective in reducing painful symptoms.8. Palliative care
Palliative care is an important aspect of management that re-
quires multidisciplinary input as outlined in the introduction.
Integrated coordination between cancer teams and local sup-
port teams is vital and should be initiated early in the course
of management.
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